Regeneron Pharmaceuticals (REGN) Revenue — Quarter Ended Dec 31, 2024
Revenue in the reporting quarter rose compared to the prior quarter and also increased relative to the same period a year earlier. The sequential growth, while positive, was smaller than the gain reported in the immediately preceding quarter.
Key takeaway
Quarter ended Dec 31, 2024 · FY2024 Q4
Revenue in the reporting quarter rose compared to the prior quarter and also increased relative to the same period a year earlier. The sequential growth, while positive, was smaller than the gain reported in the immediately preceding quarter.
Financial snapshot
Reported revenue, sequential change, year-over-year change, and trailing four-quarter revenue.
Quarter revenue
$3.8B
Revenue reported for this quarter.
Quarter-over-quarter
+1.8%
Change from the immediately preceding quarter.
Year-over-year
+10.3%
Change from the comparable year-ago quarter.
Trailing four quarters
$14.2B
Sum of the latest four reported quarters.
Quarterly revenue trend
The latest four reported quarters with year-over-year comparisons.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Mar 31, 2024 | $3.1B | -0.5% |
| Jun 30, 2024 | $3.5B | +12.3% |
| Sep 30, 2024 | $3.7B | +10.6% |
| Dec 31, 2024 | $3.8B | +10.3% |
Revenue performance
The reported revenue direction was upward, continuing the trajectory of sequential increases seen throughout the fiscal year.
Quarterly comparison
Compared with the immediately preceding quarter, revenue growth slowed. On a year-over-year basis, the reported revenue was higher than the same quarter one year earlier.
What to watch
The filing context discusses risks related to manufacturing expansion and regulatory compliance, which could impact future revenue generation.